Arkolith/Insider Trading/KNSA/Form 4

Tessari Eben

CHIEF OPERATING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Nov 19, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$514K
Net Open-Market Flow
-$514K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 17, 2025Sell(S)645$40.08$26K35K
Nov 17, 2025Sell(S)12K$41.30$488K23K
Nov 17, 2025Option exercise(M)7K$8.83$57K35K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 17, 2025Option exercise(M)7K—$06K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001867899-25-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML